nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Capecitabine—colon cancer	0.105	0.441	CbGbCtD
Bexarotene—CYP2C9—Fluorouracil—colon cancer	0.062	0.262	CbGbCtD
Bexarotene—CYP3A4—Irinotecan—colon cancer	0.0376	0.158	CbGbCtD
Bexarotene—CYP3A4—Vincristine—colon cancer	0.0328	0.139	CbGbCtD
Bexarotene—RXRG—Regulation of Androgen receptor activity—SPDEF—colon cancer	0.0242	0.103	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—SPDEF—colon cancer	0.0227	0.0971	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—SPDEF—colon cancer	0.0118	0.0506	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—HNF4A—colon cancer	0.00809	0.0346	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—HNF4A—colon cancer	0.00761	0.0325	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—HNF4A—colon cancer	0.00639	0.0273	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—HNF4A—colon cancer	0.00601	0.0257	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—PPARG—colon cancer	0.00476	0.0203	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—colon cancer	0.00447	0.0191	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—HNF4A—colon cancer	0.00396	0.0169	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—PPARG—colon cancer	0.00351	0.015	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—PPARG—colon cancer	0.0033	0.0141	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—HNF4A—colon cancer	0.00313	0.0134	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—CDH1—colon cancer	0.00293	0.0125	CbGpPWpGaD
Bexarotene—RXRA—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00284	0.0121	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—EP300—colon cancer	0.00278	0.0119	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.00278	0.0119	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—CDH1—colon cancer	0.00275	0.0118	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—colon cancer	0.00271	0.0116	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—PPARG—colon cancer	0.00266	0.0114	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—EP300—colon cancer	0.00261	0.0112	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.00261	0.0112	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—colon cancer	0.00254	0.0109	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—colon cancer	0.00233	0.00997	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.00224	0.00959	CbGpPWpGaD
Bexarotene—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00212	0.00906	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.0019	0.00811	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—EP300—colon cancer	0.00176	0.00753	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—PPARG—colon cancer	0.00172	0.00736	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—SRC—colon cancer	0.00171	0.00732	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—colon cancer	0.00171	0.00732	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—AKT1—colon cancer	0.00168	0.00717	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—CCND1—colon cancer	0.00166	0.00709	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—EP300—colon cancer	0.00166	0.00708	CbGpPWpGaD
Bexarotene—RXRA—REV-ERBA represses gene expression—EP300—colon cancer	0.00163	0.00695	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—SRC—colon cancer	0.00161	0.00688	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—colon cancer	0.00161	0.00688	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—colon cancer	0.00158	0.00674	CbGpPWpGaD
Bexarotene—RXRA—RORA activates circadian gene expression—EP300—colon cancer	0.00157	0.00673	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—PIK3CA—colon cancer	0.00148	0.00635	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.00148	0.00633	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—CDH1—colon cancer	0.00143	0.00613	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—PIK3CA—colon cancer	0.0014	0.00597	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—colon cancer	0.00137	0.00587	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—EP300—colon cancer	0.00136	0.00582	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.00136	0.00582	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—MYC—colon cancer	0.00133	0.00568	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—colon cancer	0.00133	0.00567	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—PPARG—colon cancer	0.00131	0.00561	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.00129	0.00553	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—colon cancer	0.00129	0.00552	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—AKT1—colon cancer	0.00121	0.00519	CbGpPWpGaD
Bexarotene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.00116	0.00496	CbGpPWpGaD
Bexarotene—RXRA—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—colon cancer	0.00115	0.00492	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—colon cancer	0.00114	0.00488	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—HNF4A—colon cancer	0.0011	0.00472	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.00109	0.00466	CbGpPWpGaD
Bexarotene—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.00106	0.00453	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—HNF4A—colon cancer	0.00104	0.00444	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.00103	0.0044	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.00101	0.00432	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—colon cancer	0.000978	0.00418	CbGpPWpGaD
Bexarotene—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000976	0.00417	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—CTNNB1—colon cancer	0.000924	0.00395	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—CDKN1A—colon cancer	0.000903	0.00386	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000871	0.00372	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—EP300—colon cancer	0.000863	0.00369	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—SRC—colon cancer	0.000839	0.00359	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—colon cancer	0.000838	0.00358	CbGpPWpGaD
Bexarotene—RXRA—Circadian Clock—EP300—colon cancer	0.000838	0.00358	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—AKT1—colon cancer	0.000822	0.00352	CbGpPWpGaD
Bexarotene—Cough—Irinotecan—colon cancer	0.000796	0.0015	CcSEcCtD
Bexarotene—Weight decreased—Capecitabine—colon cancer	0.000793	0.0015	CcSEcCtD
Bexarotene—Hyperglycaemia—Capecitabine—colon cancer	0.00079	0.00149	CcSEcCtD
Bexarotene—RXRA—Metabolism—CA7—colon cancer	0.00079	0.00338	CbGpPWpGaD
Bexarotene—Hypertension—Irinotecan—colon cancer	0.000787	0.00149	CcSEcCtD
Bexarotene—Pneumonia—Capecitabine—colon cancer	0.000786	0.00148	CcSEcCtD
Bexarotene—Leukopenia—Fluorouracil—colon cancer	0.000782	0.00148	CcSEcCtD
Bexarotene—Lethargy—Methotrexate—colon cancer	0.00077	0.00146	CcSEcCtD
Bexarotene—Cerebrovascular accident—Methotrexate—colon cancer	0.00077	0.00146	CcSEcCtD
Bexarotene—Discomfort—Irinotecan—colon cancer	0.000767	0.00145	CcSEcCtD
Bexarotene—Neuropathy peripheral—Capecitabine—colon cancer	0.000766	0.00145	CcSEcCtD
Bexarotene—Oedema—Vincristine—colon cancer	0.000764	0.00144	CcSEcCtD
Bexarotene—Stomatitis—Capecitabine—colon cancer	0.000761	0.00144	CcSEcCtD
Bexarotene—Jaundice—Capecitabine—colon cancer	0.000761	0.00144	CcSEcCtD
Bexarotene—Infection—Vincristine—colon cancer	0.000759	0.00144	CcSEcCtD
Bexarotene—Conjunctivitis—Capecitabine—colon cancer	0.000759	0.00144	CcSEcCtD
Bexarotene—Urinary tract infection—Capecitabine—colon cancer	0.000759	0.00144	CcSEcCtD
Bexarotene—Osteoarthritis—Methotrexate—colon cancer	0.000755	0.00143	CcSEcCtD
Bexarotene—Confusional state—Irinotecan—colon cancer	0.000751	0.00142	CcSEcCtD
Bexarotene—Nervous system disorder—Vincristine—colon cancer	0.00075	0.00142	CcSEcCtD
Bexarotene—Thrombocytopenia—Vincristine—colon cancer	0.000748	0.00141	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—TGFB1—colon cancer	0.000747	0.00319	CbGpPWpGaD
Bexarotene—Haematuria—Capecitabine—colon cancer	0.000745	0.00141	CcSEcCtD
Bexarotene—Oedema—Irinotecan—colon cancer	0.000744	0.00141	CcSEcCtD
Bexarotene—Myalgia—Fluorouracil—colon cancer	0.000744	0.00141	CcSEcCtD
Bexarotene—Chest pain—Fluorouracil—colon cancer	0.000744	0.00141	CcSEcCtD
Bexarotene—Infection—Irinotecan—colon cancer	0.000739	0.0014	CcSEcCtD
Bexarotene—Hyperhidrosis—Vincristine—colon cancer	0.000739	0.0014	CcSEcCtD
Bexarotene—Epistaxis—Capecitabine—colon cancer	0.000737	0.00139	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—PPARG—colon cancer	0.000735	0.00314	CbGpPWpGaD
Bexarotene—Discomfort—Fluorouracil—colon cancer	0.000735	0.00139	CcSEcCtD
Bexarotene—Shock—Irinotecan—colon cancer	0.000732	0.00138	CcSEcCtD
Bexarotene—Nervous system disorder—Irinotecan—colon cancer	0.00073	0.00138	CcSEcCtD
Bexarotene—Thrombocytopenia—Irinotecan—colon cancer	0.000729	0.00138	CcSEcCtD
Bexarotene—Anorexia—Vincristine—colon cancer	0.000729	0.00138	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—PIK3CA—colon cancer	0.000728	0.00311	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.00072	0.00308	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Irinotecan—colon cancer	0.00072	0.00136	CcSEcCtD
Bexarotene—Confusional state—Fluorouracil—colon cancer	0.000719	0.00136	CcSEcCtD
Bexarotene—Mood swings—Methotrexate—colon cancer	0.000715	0.00135	CcSEcCtD
Bexarotene—Oedema—Fluorouracil—colon cancer	0.000713	0.00135	CcSEcCtD
Bexarotene—Anorexia—Irinotecan—colon cancer	0.00071	0.00134	CcSEcCtD
Bexarotene—Ataxia—Methotrexate—colon cancer	0.000709	0.00134	CcSEcCtD
Bexarotene—Infection—Fluorouracil—colon cancer	0.000708	0.00134	CcSEcCtD
Bexarotene—Haemoglobin—Capecitabine—colon cancer	0.000705	0.00133	CcSEcCtD
Bexarotene—Rhinitis—Capecitabine—colon cancer	0.000703	0.00133	CcSEcCtD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000702	0.003	CbGpPWpGaD
Bexarotene—Haemorrhage—Capecitabine—colon cancer	0.000701	0.00133	CcSEcCtD
Bexarotene—Nervous system disorder—Fluorouracil—colon cancer	0.000699	0.00132	CcSEcCtD
Bexarotene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000699	0.00299	CbGpPWpGaD
Bexarotene—Thrombocytopenia—Fluorouracil—colon cancer	0.000698	0.00132	CcSEcCtD
Bexarotene—Hypoaesthesia—Capecitabine—colon cancer	0.000698	0.00132	CcSEcCtD
Bexarotene—Liver function test abnormal—Methotrexate—colon cancer	0.000697	0.00132	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Vincristine—colon cancer	0.000696	0.00132	CcSEcCtD
Bexarotene—Pharyngitis—Capecitabine—colon cancer	0.000696	0.00132	CcSEcCtD
Bexarotene—Tachycardia—Fluorouracil—colon cancer	0.000696	0.00132	CcSEcCtD
Bexarotene—Urinary tract disorder—Capecitabine—colon cancer	0.000692	0.00131	CcSEcCtD
Bexarotene—Insomnia—Vincristine—colon cancer	0.000691	0.00131	CcSEcCtD
Bexarotene—Oedema peripheral—Capecitabine—colon cancer	0.000691	0.00131	CcSEcCtD
Bexarotene—Connective tissue disorder—Capecitabine—colon cancer	0.000689	0.0013	CcSEcCtD
Bexarotene—Urethral disorder—Capecitabine—colon cancer	0.000687	0.0013	CcSEcCtD
Bexarotene—Paraesthesia—Vincristine—colon cancer	0.000686	0.0013	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.00068	0.00291	CbGpPWpGaD
Bexarotene—Anorexia—Fluorouracil—colon cancer	0.00068	0.00128	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000679	0.0029	CbGpPWpGaD
Bexarotene—Insomnia—Irinotecan—colon cancer	0.000673	0.00127	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—colon cancer	0.000673	0.00288	CbGpPWpGaD
Bexarotene—Paraesthesia—Irinotecan—colon cancer	0.000668	0.00126	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000668	0.00285	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000666	0.00285	CbGpPWpGaD
Bexarotene—Decreased appetite—Vincristine—colon cancer	0.000664	0.00126	CcSEcCtD
Bexarotene—Dyspnoea—Irinotecan—colon cancer	0.000664	0.00125	CcSEcCtD
Bexarotene—Somnolence—Irinotecan—colon cancer	0.000662	0.00125	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Vincristine—colon cancer	0.00066	0.00125	CcSEcCtD
Bexarotene—Fatigue—Vincristine—colon cancer	0.000659	0.00125	CcSEcCtD
Bexarotene—Eye disorder—Capecitabine—colon cancer	0.000655	0.00124	CcSEcCtD
Bexarotene—Dyspepsia—Irinotecan—colon cancer	0.000655	0.00124	CcSEcCtD
Bexarotene—Tinnitus—Capecitabine—colon cancer	0.000654	0.00124	CcSEcCtD
Bexarotene—Pain—Vincristine—colon cancer	0.000654	0.00124	CcSEcCtD
Bexarotene—Constipation—Vincristine—colon cancer	0.000654	0.00124	CcSEcCtD
Bexarotene—Cardiac disorder—Capecitabine—colon cancer	0.000651	0.00123	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00065	0.00123	CcSEcCtD
Bexarotene—Decreased appetite—Irinotecan—colon cancer	0.000647	0.00122	CcSEcCtD
Bexarotene—Eosinophilia—Methotrexate—colon cancer	0.000646	0.00122	CcSEcCtD
Bexarotene—Insomnia—Fluorouracil—colon cancer	0.000645	0.00122	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—PPARG—colon cancer	0.000643	0.00275	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000643	0.00275	CbGpPWpGaD
Bexarotene—Gastrointestinal disorder—Irinotecan—colon cancer	0.000643	0.00121	CcSEcCtD
Bexarotene—Fatigue—Irinotecan—colon cancer	0.000642	0.00121	CcSEcCtD
Bexarotene—Paraesthesia—Fluorouracil—colon cancer	0.00064	0.00121	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—EP300—colon cancer	0.00064	0.00274	CbGpPWpGaD
Bexarotene—Pancreatitis—Methotrexate—colon cancer	0.000639	0.00121	CcSEcCtD
Bexarotene—Constipation—Irinotecan—colon cancer	0.000637	0.0012	CcSEcCtD
Bexarotene—Pain—Irinotecan—colon cancer	0.000637	0.0012	CcSEcCtD
Bexarotene—Angiopathy—Capecitabine—colon cancer	0.000636	0.0012	CcSEcCtD
Bexarotene—Dyspnoea—Fluorouracil—colon cancer	0.000636	0.0012	CcSEcCtD
Bexarotene—Somnolence—Fluorouracil—colon cancer	0.000634	0.0012	CcSEcCtD
Bexarotene—Chills—Capecitabine—colon cancer	0.000629	0.00119	CcSEcCtD
Bexarotene—Dyspepsia—Fluorouracil—colon cancer	0.000628	0.00119	CcSEcCtD
Bexarotene—Arrhythmia—Capecitabine—colon cancer	0.000626	0.00118	CcSEcCtD
Bexarotene—Gastrointestinal pain—Vincristine—colon cancer	0.000625	0.00118	CcSEcCtD
Bexarotene—Decreased appetite—Fluorouracil—colon cancer	0.00062	0.00117	CcSEcCtD
Bexarotene—Alopecia—Capecitabine—colon cancer	0.00062	0.00117	CcSEcCtD
Bexarotene—Pancytopenia—Methotrexate—colon cancer	0.000619	0.00117	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000615	0.00116	CcSEcCtD
Bexarotene—Feeling abnormal—Irinotecan—colon cancer	0.000613	0.00116	CcSEcCtD
Bexarotene—Erythema—Capecitabine—colon cancer	0.00061	0.00115	CcSEcCtD
Bexarotene—Malnutrition—Capecitabine—colon cancer	0.00061	0.00115	CcSEcCtD
Bexarotene—Neutropenia—Methotrexate—colon cancer	0.00061	0.00115	CcSEcCtD
Bexarotene—Dysuria—Methotrexate—colon cancer	0.00061	0.00115	CcSEcCtD
Bexarotene—Pain—Fluorouracil—colon cancer	0.00061	0.00115	CcSEcCtD
Bexarotene—Gastrointestinal pain—Irinotecan—colon cancer	0.000609	0.00115	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—DCC—colon cancer	0.000605	0.00259	CbGpPWpGaD
Bexarotene—Abdominal pain—Vincristine—colon cancer	0.000604	0.00114	CcSEcCtD
Bexarotene—Body temperature increased—Vincristine—colon cancer	0.000604	0.00114	CcSEcCtD
Bexarotene—Flatulence—Capecitabine—colon cancer	0.000601	0.00114	CcSEcCtD
Bexarotene—Erectile dysfunction—Methotrexate—colon cancer	0.000601	0.00114	CcSEcCtD
Bexarotene—Dysgeusia—Capecitabine—colon cancer	0.000598	0.00113	CcSEcCtD
Bexarotene—Photosensitivity reaction—Methotrexate—colon cancer	0.000595	0.00113	CcSEcCtD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—colon cancer	0.000594	0.00254	CbGpPWpGaD
Bexarotene—Back pain—Capecitabine—colon cancer	0.00059	0.00112	CcSEcCtD
Bexarotene—Body temperature increased—Irinotecan—colon cancer	0.000588	0.00111	CcSEcCtD
Bexarotene—Abdominal pain—Irinotecan—colon cancer	0.000588	0.00111	CcSEcCtD
Bexarotene—Feeling abnormal—Fluorouracil—colon cancer	0.000587	0.00111	CcSEcCtD
Bexarotene—Muscle spasms—Capecitabine—colon cancer	0.000587	0.00111	CcSEcCtD
Bexarotene—Pneumonia—Methotrexate—colon cancer	0.000585	0.00111	CcSEcCtD
Bexarotene—Stomatitis—Methotrexate—colon cancer	0.000567	0.00107	CcSEcCtD
Bexarotene—Ill-defined disorder—Capecitabine—colon cancer	0.000566	0.00107	CcSEcCtD
Bexarotene—Conjunctivitis—Methotrexate—colon cancer	0.000565	0.00107	CcSEcCtD
Bexarotene—Anaemia—Capecitabine—colon cancer	0.000564	0.00107	CcSEcCtD
Bexarotene—Body temperature increased—Fluorouracil—colon cancer	0.000564	0.00107	CcSEcCtD
Bexarotene—Hypersensitivity—Vincristine—colon cancer	0.000563	0.00106	CcSEcCtD
Bexarotene—Sweating—Methotrexate—colon cancer	0.000557	0.00105	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TGFB1—colon cancer	0.000556	0.00238	CbGpPWpGaD
Bexarotene—Haematuria—Methotrexate—colon cancer	0.000554	0.00105	CcSEcCtD
Bexarotene—Malaise—Capecitabine—colon cancer	0.00055	0.00104	CcSEcCtD
Bexarotene—Epistaxis—Methotrexate—colon cancer	0.000548	0.00104	CcSEcCtD
Bexarotene—Vertigo—Capecitabine—colon cancer	0.000548	0.00104	CcSEcCtD
Bexarotene—Hypersensitivity—Irinotecan—colon cancer	0.000548	0.00104	CcSEcCtD
Bexarotene—Asthenia—Vincristine—colon cancer	0.000548	0.00104	CcSEcCtD
Bexarotene—Syncope—Capecitabine—colon cancer	0.000547	0.00103	CcSEcCtD
Bexarotene—Leukopenia—Capecitabine—colon cancer	0.000546	0.00103	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—HNF4A—colon cancer	0.000541	0.00231	CbGpPWpGaD
Bexarotene—Palpitations—Capecitabine—colon cancer	0.000539	0.00102	CcSEcCtD
Bexarotene—Loss of consciousness—Capecitabine—colon cancer	0.000536	0.00101	CcSEcCtD
Bexarotene—Asthenia—Irinotecan—colon cancer	0.000534	0.00101	CcSEcCtD
Bexarotene—Cough—Capecitabine—colon cancer	0.000533	0.00101	CcSEcCtD
Bexarotene—RXRG—Gene Expression—HNF4A—colon cancer	0.000532	0.00227	CbGpPWpGaD
Bexarotene—Hypertension—Capecitabine—colon cancer	0.000527	0.000996	CcSEcCtD
Bexarotene—Hypersensitivity—Fluorouracil—colon cancer	0.000525	0.000993	CcSEcCtD
Bexarotene—Haemoglobin—Methotrexate—colon cancer	0.000525	0.000992	CcSEcCtD
Bexarotene—Diarrhoea—Vincristine—colon cancer	0.000523	0.000988	CcSEcCtD
Bexarotene—Haemorrhage—Methotrexate—colon cancer	0.000522	0.000987	CcSEcCtD
Bexarotene—Arthralgia—Capecitabine—colon cancer	0.00052	0.000982	CcSEcCtD
Bexarotene—Chest pain—Capecitabine—colon cancer	0.00052	0.000982	CcSEcCtD
Bexarotene—Myalgia—Capecitabine—colon cancer	0.00052	0.000982	CcSEcCtD
Bexarotene—Pharyngitis—Methotrexate—colon cancer	0.000518	0.000979	CcSEcCtD
Bexarotene—Anxiety—Capecitabine—colon cancer	0.000518	0.000979	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000516	0.000975	CcSEcCtD
Bexarotene—Urinary tract disorder—Methotrexate—colon cancer	0.000515	0.000974	CcSEcCtD
Bexarotene—Discomfort—Capecitabine—colon cancer	0.000513	0.00097	CcSEcCtD
Bexarotene—Urethral disorder—Methotrexate—colon cancer	0.000512	0.000967	CcSEcCtD
Bexarotene—Diarrhoea—Irinotecan—colon cancer	0.000509	0.000963	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—HNF4A—colon cancer	0.000509	0.00218	CbGpPWpGaD
Bexarotene—Dry mouth—Capecitabine—colon cancer	0.000508	0.000961	CcSEcCtD
Bexarotene—Dizziness—Vincristine—colon cancer	0.000505	0.000955	CcSEcCtD
Bexarotene—Pruritus—Fluorouracil—colon cancer	0.000504	0.000953	CcSEcCtD
Bexarotene—Confusional state—Capecitabine—colon cancer	0.000502	0.000949	CcSEcCtD
Bexarotene—RXRB—Gene Expression—HNF4A—colon cancer	0.0005	0.00214	CbGpPWpGaD
Bexarotene—Oedema—Capecitabine—colon cancer	0.000498	0.000942	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000496	0.00212	CbGpPWpGaD
Bexarotene—Infection—Capecitabine—colon cancer	0.000495	0.000935	CcSEcCtD
Bexarotene—Dizziness—Irinotecan—colon cancer	0.000492	0.00093	CcSEcCtD
Bexarotene—Shock—Capecitabine—colon cancer	0.00049	0.000926	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.00049	0.0021	CbGpPWpGaD
Bexarotene—Nervous system disorder—Capecitabine—colon cancer	0.000489	0.000923	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—colon cancer	0.000488	0.000922	CcSEcCtD
Bexarotene—Diarrhoea—Fluorouracil—colon cancer	0.000488	0.000922	CcSEcCtD
Bexarotene—Thrombocytopenia—Capecitabine—colon cancer	0.000488	0.000922	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—colon cancer	0.000487	0.00092	CcSEcCtD
Bexarotene—Tachycardia—Capecitabine—colon cancer	0.000486	0.000919	CcSEcCtD
Bexarotene—Vomiting—Vincristine—colon cancer	0.000486	0.000918	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—colon cancer	0.000484	0.000916	CcSEcCtD
Bexarotene—Skin disorder—Capecitabine—colon cancer	0.000484	0.000915	CcSEcCtD
Bexarotene—Rash—Vincristine—colon cancer	0.000482	0.000911	CcSEcCtD
Bexarotene—Hyperhidrosis—Capecitabine—colon cancer	0.000482	0.00091	CcSEcCtD
Bexarotene—Dermatitis—Vincristine—colon cancer	0.000481	0.00091	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—EP300—colon cancer	0.000481	0.00206	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—PPARG—colon cancer	0.000479	0.00205	CbGpPWpGaD
Bexarotene—Headache—Vincristine—colon cancer	0.000479	0.000905	CcSEcCtD
Bexarotene—RXRA—Metabolism—CHST5—colon cancer	0.000478	0.00205	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ODC1—colon cancer	0.000478	0.00205	CbGpPWpGaD
Bexarotene—Anorexia—Capecitabine—colon cancer	0.000475	0.000898	CcSEcCtD
Bexarotene—Angiopathy—Methotrexate—colon cancer	0.000474	0.000895	CcSEcCtD
Bexarotene—Vomiting—Irinotecan—colon cancer	0.000473	0.000894	CcSEcCtD
Bexarotene—Dizziness—Fluorouracil—colon cancer	0.000471	0.000891	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000471	0.00201	CbGpPWpGaD
Bexarotene—Rash—Irinotecan—colon cancer	0.000469	0.000887	CcSEcCtD
Bexarotene—Dermatitis—Irinotecan—colon cancer	0.000469	0.000886	CcSEcCtD
Bexarotene—Chills—Methotrexate—colon cancer	0.000468	0.000885	CcSEcCtD
Bexarotene—Headache—Irinotecan—colon cancer	0.000466	0.000881	CcSEcCtD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000463	0.00198	CbGpPWpGaD
Bexarotene—Alopecia—Methotrexate—colon cancer	0.000461	0.000872	CcSEcCtD
Bexarotene—Erythema—Methotrexate—colon cancer	0.000454	0.000859	CcSEcCtD
Bexarotene—Malnutrition—Methotrexate—colon cancer	0.000454	0.000859	CcSEcCtD
Bexarotene—Nausea—Vincristine—colon cancer	0.000454	0.000858	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000454	0.000858	CcSEcCtD
Bexarotene—Vomiting—Fluorouracil—colon cancer	0.000453	0.000857	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—CTNNB1—colon cancer	0.000453	0.00194	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—PPARG—colon cancer	0.000451	0.00193	CbGpPWpGaD
Bexarotene—Insomnia—Capecitabine—colon cancer	0.000451	0.000852	CcSEcCtD
Bexarotene—Rash—Fluorouracil—colon cancer	0.000449	0.00085	CcSEcCtD
Bexarotene—Dermatitis—Fluorouracil—colon cancer	0.000449	0.000849	CcSEcCtD
Bexarotene—Paraesthesia—Capecitabine—colon cancer	0.000447	0.000845	CcSEcCtD
Bexarotene—Headache—Fluorouracil—colon cancer	0.000447	0.000844	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—colon cancer	0.000445	0.000841	CcSEcCtD
Bexarotene—Dyspnoea—Capecitabine—colon cancer	0.000444	0.000839	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—CDKN1A—colon cancer	0.000442	0.00189	CbGpPWpGaD
Bexarotene—Nausea—Irinotecan—colon cancer	0.000442	0.000836	CcSEcCtD
Bexarotene—Back pain—Methotrexate—colon cancer	0.00044	0.000831	CcSEcCtD
Bexarotene—Dyspepsia—Capecitabine—colon cancer	0.000439	0.000829	CcSEcCtD
Bexarotene—Decreased appetite—Capecitabine—colon cancer	0.000433	0.000818	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Capecitabine—colon cancer	0.00043	0.000813	CcSEcCtD
Bexarotene—Fatigue—Capecitabine—colon cancer	0.00043	0.000812	CcSEcCtD
Bexarotene—Constipation—Capecitabine—colon cancer	0.000426	0.000805	CcSEcCtD
Bexarotene—Pain—Capecitabine—colon cancer	0.000426	0.000805	CcSEcCtD
Bexarotene—Nausea—Fluorouracil—colon cancer	0.000423	0.0008	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—colon cancer	0.000422	0.000797	CcSEcCtD
Bexarotene—Anaemia—Methotrexate—colon cancer	0.00042	0.000794	CcSEcCtD
Bexarotene—Feeling abnormal—Capecitabine—colon cancer	0.000411	0.000776	CcSEcCtD
Bexarotene—Malaise—Methotrexate—colon cancer	0.00041	0.000774	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—colon cancer	0.000408	0.000772	CcSEcCtD
Bexarotene—Gastrointestinal pain—Capecitabine—colon cancer	0.000407	0.00077	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—colon cancer	0.000407	0.000769	CcSEcCtD
Bexarotene—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	0.000406	0.00174	CbGpPWpGaD
Bexarotene—Cough—Methotrexate—colon cancer	0.000397	0.000749	CcSEcCtD
Bexarotene—Abdominal pain—Capecitabine—colon cancer	0.000394	0.000744	CcSEcCtD
Bexarotene—Body temperature increased—Capecitabine—colon cancer	0.000394	0.000744	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—colon cancer	0.000387	0.000731	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—colon cancer	0.000387	0.000731	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—colon cancer	0.000387	0.000731	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000384	0.000726	CcSEcCtD
Bexarotene—Discomfort—Methotrexate—colon cancer	0.000382	0.000722	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—colon cancer	0.000374	0.000707	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000372	0.00159	CbGpPWpGaD
Bexarotene—Infection—Methotrexate—colon cancer	0.000368	0.000696	CcSEcCtD
Bexarotene—Hypersensitivity—Capecitabine—colon cancer	0.000367	0.000694	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—TGFB1—colon cancer	0.000366	0.00156	CbGpPWpGaD
Bexarotene—Nervous system disorder—Methotrexate—colon cancer	0.000364	0.000687	CcSEcCtD
Bexarotene—Thrombocytopenia—Methotrexate—colon cancer	0.000363	0.000686	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—colon cancer	0.00036	0.000681	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—colon cancer	0.000359	0.000678	CcSEcCtD
Bexarotene—Asthenia—Capecitabine—colon cancer	0.000357	0.000676	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—colon cancer	0.000354	0.000668	CcSEcCtD
Bexarotene—Pruritus—Capecitabine—colon cancer	0.000352	0.000666	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000345	0.00148	CbGpPWpGaD
Bexarotene—Diarrhoea—Capecitabine—colon cancer	0.000341	0.000644	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000338	0.000639	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000336	0.00144	CbGpPWpGaD
Bexarotene—Insomnia—Methotrexate—colon cancer	0.000335	0.000634	CcSEcCtD
Bexarotene—RXRA—NRF2 pathway—TGFB1—colon cancer	0.000333	0.00143	CbGpPWpGaD
Bexarotene—Paraesthesia—Methotrexate—colon cancer	0.000333	0.000629	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000333	0.00142	CbGpPWpGaD
Bexarotene—Dyspnoea—Methotrexate—colon cancer	0.000331	0.000625	CcSEcCtD
Bexarotene—Somnolence—Methotrexate—colon cancer	0.00033	0.000623	CcSEcCtD
Bexarotene—Dizziness—Capecitabine—colon cancer	0.000329	0.000623	CcSEcCtD
Bexarotene—Dyspepsia—Methotrexate—colon cancer	0.000326	0.000617	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000325	0.00139	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000324	0.00139	CbGpPWpGaD
Bexarotene—Decreased appetite—Methotrexate—colon cancer	0.000322	0.000609	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—colon cancer	0.00032	0.000605	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—colon cancer	0.00032	0.000604	CcSEcCtD
Bexarotene—Pain—Methotrexate—colon cancer	0.000317	0.000599	CcSEcCtD
Bexarotene—Vomiting—Capecitabine—colon cancer	0.000317	0.000599	CcSEcCtD
Bexarotene—Rash—Capecitabine—colon cancer	0.000314	0.000594	CcSEcCtD
Bexarotene—Dermatitis—Capecitabine—colon cancer	0.000314	0.000593	CcSEcCtD
Bexarotene—Headache—Capecitabine—colon cancer	0.000312	0.00059	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000309	0.00132	CbGpPWpGaD
Bexarotene—Feeling abnormal—Methotrexate—colon cancer	0.000306	0.000578	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—colon cancer	0.000303	0.000573	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000301	0.00129	CbGpPWpGaD
Bexarotene—Nausea—Capecitabine—colon cancer	0.000296	0.000559	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—CA7—colon cancer	0.000295	0.00126	CbGpPWpGaD
Bexarotene—Abdominal pain—Methotrexate—colon cancer	0.000293	0.000554	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—colon cancer	0.000293	0.000554	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000293	0.00125	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—MYC—colon cancer	0.000273	0.00117	CbGpPWpGaD
Bexarotene—Hypersensitivity—Methotrexate—colon cancer	0.000273	0.000516	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—ABCB1—colon cancer	0.00027	0.00115	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.00027	0.00115	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000269	0.00115	CbGpPWpGaD
Bexarotene—Asthenia—Methotrexate—colon cancer	0.000266	0.000503	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000264	0.00113	CbGpPWpGaD
Bexarotene—Pruritus—Methotrexate—colon cancer	0.000262	0.000496	CcSEcCtD
Bexarotene—RXRA—Gene Expression—HNF4A—colon cancer	0.00026	0.00111	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—MYC—colon cancer	0.000257	0.0011	CbGpPWpGaD
Bexarotene—Diarrhoea—Methotrexate—colon cancer	0.000254	0.00048	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000249	0.00107	CbGpPWpGaD
Bexarotene—Dizziness—Methotrexate—colon cancer	0.000245	0.000464	CcSEcCtD
Bexarotene—Vomiting—Methotrexate—colon cancer	0.000236	0.000446	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—PPARG—colon cancer	0.000235	0.001	CbGpPWpGaD
Bexarotene—Rash—Methotrexate—colon cancer	0.000234	0.000442	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—colon cancer	0.000234	0.000442	CcSEcCtD
Bexarotene—Headache—Methotrexate—colon cancer	0.000232	0.000439	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PPARG—colon cancer	0.000231	0.000987	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000229	0.000979	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000221	0.000947	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PPARG—colon cancer	0.000221	0.000945	CbGpPWpGaD
Bexarotene—Nausea—Methotrexate—colon cancer	0.00022	0.000416	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PPARG—colon cancer	0.000217	0.000928	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000197	0.000844	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CA7—colon cancer	0.000194	0.000831	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000187	0.000799	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CHST5—colon cancer	0.000179	0.000764	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ODC1—colon cancer	0.000179	0.000764	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CTNNB1—colon cancer	0.000156	0.000666	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000155	0.000664	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EP300—colon cancer	0.000145	0.000619	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—SRC—colon cancer	0.000141	0.000602	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—VEGFA—colon cancer	0.000137	0.000586	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NRAS—colon cancer	0.000135	0.000579	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—MYC—colon cancer	0.000134	0.000573	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MYC—colon cancer	0.000132	0.000563	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000129	0.000552	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ABCB1—colon cancer	0.000126	0.000541	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TGFB1—colon cancer	0.000126	0.000538	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TYMS—colon cancer	0.000124	0.000531	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MYC—colon cancer	0.000124	0.000529	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—colon cancer	0.000123	0.000527	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ODC1—colon cancer	0.000118	0.000504	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CHST5—colon cancer	0.000118	0.000504	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—KRAS—colon cancer	0.000116	0.000498	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PPARG—colon cancer	0.000113	0.000484	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—colon cancer	9.9e-05	0.000423	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.56e-05	0.000409	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—AKT1—colon cancer	9.13e-05	0.00039	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PPARG—colon cancer	8.79e-05	0.000376	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—AKT1—colon cancer	8.74e-05	0.000374	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—AKT1—colon cancer	8.58e-05	0.000367	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.37e-05	0.000315	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS2—colon cancer	6.92e-05	0.000296	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MYC—colon cancer	6.45e-05	0.000276	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.8e-05	0.000248	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—EP300—colon cancer	5.75e-05	0.000246	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.82e-05	0.000206	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ABCB1—colon cancer	4.72e-05	0.000202	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TYMS—colon cancer	4.63e-05	0.000198	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—AKT1—colon cancer	4.47e-05	0.000191	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CA—colon cancer	4.26e-05	0.000182	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.57e-05	0.000153	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKT1—colon cancer	3.48e-05	0.000149	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PPARG—colon cancer	3.28e-05	0.00014	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ABCB1—colon cancer	3.11e-05	0.000133	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TYMS—colon cancer	3.06e-05	0.000131	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS2—colon cancer	2.58e-05	0.00011	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PPARG—colon cancer	2.17e-05	9.26e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—EP300—colon cancer	2.15e-05	9.19e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS2—colon cancer	1.7e-05	7.28e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CA—colon cancer	1.59e-05	6.79e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—EP300—colon cancer	1.42e-05	6.06e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKT1—colon cancer	1.3e-05	5.55e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CA—colon cancer	1.05e-05	4.48e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKT1—colon cancer	8.56e-06	3.66e-05	CbGpPWpGaD
